CompanyGraphAt a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionReturn on equity is 38%, higher than 95% of its Biotechnology peers (median -22.3%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
428.99MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
-47.20%vs all stocks
Market Capitalization
428.99MUSDvs all stocks (USD)
Enterprise Value
150.03MUSDvs all stocks (USD)
Forward P/E
-1.25xvs Biotechnology peers
Price to Book (MRQ)
0.9193xvs Biotechnology peers
Enterprise to EBITDA
-0.4730xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-56.10%vs Biotechnology peers
Return on Equity (TTM)
37.96%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 27, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-317.23MUSDvs all stocks (USD)
Net Income (TTM)
-322.16MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-256.02MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-333.64MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-338.94MUSDvs all stocks (USD)
Pre-tax Income
-324.25MUSDFY2025 · Dec 31, 2025Net Income
-324.25MUSDFY2025 · Dec 31, 2025EBIT
-323.41MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-299.24MUSDFY2025 · Dec 31, 2025Research & Development
250.32MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
88.63MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
15.57MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
837.00KUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-324.25MUSDFY2025 · Dec 31, 2025Preferred Stock Dividends
9.40MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-221.19MUSDFY2025 · Dec 31, 2025Free Cash Flow
-267.94MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
113.07MUSDFY2025 · Dec 31, 2025Interest Paid
889.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-324.25MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
24.18MUSDFY2025 · Dec 31, 2025Stock-based Compensation
18.04MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-5.54MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-3.81MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
70.20MUSDFY2025 · Dec 31, 2025Capital Expenditures
-46.74MUSDFY2025 · Dec 31, 2025Purchase of Investments
-444.10MUSDFY2025 · Dec 31, 2025Sale of Investments
309.50MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-181.34MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
352.05MUSDFY2025 · Dec 31, 2025Shares Outstanding
54.15MSharesUpdated Sep 27, 2026Float Shares
29.67MSharesUpdated Sep 27, 2026Shares Short
5.45MSharesUpdated Sep 27, 2026Short Ratio
9.78daysvs all stocks
Short % of Shares Outstanding
13.37%vs all stocks
% Held by Insiders
17.38%vs all stocks
% Held by Institutions
72.66%vs all stocks
Total Cash (MRQ)
531.18MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
9.81USDUpdated Sep 27, 2026Total Debt (MRQ)
252.22MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.5407xvs Biotechnology peers
Current Ratio (MRQ)
9.89xvs Biotechnology peers
Book Value per Share (MRQ)
8.62USDUpdated Sep 27, 2026Total Assets
594.73MUSDvs all stocks (USD)
Total Current Assets
348.92MUSDFY2025 · Dec 31, 2025Total Liabilities
1.47BUSDFY2025 · Dec 31, 2025Total Non-current Assets
245.82MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
1.42BUSDFY2025 · Dec 31, 2025Total Current Liabilities
55.01MUSDFY2025 · Dec 31, 2025Cash
19.94MUSDFY2025 · Dec 31, 2025Cash Equivalents
84.96MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
104.90MUSDFY2025 · Dec 31, 2025Other Short-term Investments
231.07MUSDFY2025 · Dec 31, 2025Accounts Payable
681.00KUSDFY2025 · Dec 31, 2025Short-term Debt
10.03MUSDFY2025 · Dec 31, 2025Other Current Liabilities
35.00KUSDFY2025 · Dec 31, 2025Long-term Debt
247.29MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
10.00MUSDFY2025 · Dec 31, 2025Common Stock (Book)
0.00USDFY2025 · Dec 31, 2025Retained Earnings
-920.51MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-879.03MUSDvs all stocks (USD)
52-Week Low
7.72USDUpdated Sep 27, 202652-Week High
17.40USDUpdated Sep 27, 202652-Week Change
-47.20%vs all stocks
50-Day MA
9.98USDUpdated Sep 27, 2026200-Day MA
10.94USDUpdated Sep 27, 2026Avg 10-Day Volume
813.75KSharesUpdated Sep 27, 2026Avg 30-Day Volume
630.60KSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-5.96USDUpdated Sep 27, 2026Other Income / Expense
-32.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is 38%, higher than 95% of its Biotechnology peers (median -22.3%)Significant
Return on equity: 0.38Industry median: -0.22Industry P95: 0.23Peers compared: 260
Price-to-book is 0.92×, lower than 95% of its Biotechnology peers (median 2.86×)Notable
Price-to-book: 0.92Industry median: 2.86Industry P5: 0.98Peers compared: 260
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.53
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Levered free cash flow is -$333.64M, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -333,644,000Global P5: -202,685,365.334
Companies that share the same coordination system — how they create, deliver, or capture value.
DiaMedica Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Kehua Bio-Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Honz Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Prothena Corporation plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hua Medicine Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Tianmu-Shan Pharmaceutical Enterprise Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Baotou Dongbao Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang East-Asia Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tuoxin Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kyverna Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule